Stock analysts at StockNews.com assumed coverage on shares of NanoViricides (NYSE:NNVC – Get Free Report) in a research report issued on Saturday. The firm set a “sell” rating on the stock.
NanoViricides Price Performance
Shares of NYSE NNVC opened at $2.23 on Friday. NanoViricides has a 12 month low of $1.00 and a 12 month high of $2.35. The company has a market cap of $26.34 million, a P/E ratio of -2.72 and a beta of 0.70. The business’s 50 day moving average is $1.44 and its two-hundred day moving average is $1.24.
NanoViricides (NYSE:NNVC – Get Free Report) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter.
NanoViricides Company Profile
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Featured Stories
- Five stocks we like better than NanoViricides
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- MarketBeat Week in Review – 5/20 – 5/24
- EV Stocks and How to Profit from Them
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- What is Put Option Volume?
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
